The FDA has requested that the drug manufacturer Eisai, remove their weight-loss drug Belviq (lorcaserin) from the market. A safety clinical trial proves that Belviq and Belviq XR cause an increase in cancer.
Eisai submitted a request to voluntarily withdraw the drug.
After the FDA approved lorcaserin in 2012, they required the drug manufacturer to conduct a clinical trial to evaluate the risk of cardiovascular problems. As a result, a range of cancer types was reported, with several different types of cancers occurring more frequently in the lorcaserin group. These include pancreatic, colorectal, and lung cancers.